drugset
drugset / Trial / NCT02013388

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

NCT02013388 ↗

Phase 1 Completed 49 enrolled Nivalis Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study in healthy subjects to assess the safety, tolerability, and pharmacokinetics of N91115.

Timeline

Start
2014-02
Primary completion
2014-12
Completion
2015-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cavosonstat Small molecule 10 mg Oral
Subject Cavosonstat Small molecule 50 mg Oral
Subject Cavosonstat Small molecule 250 mg Oral
Subject Cavosonstat Small molecule 500 mg Oral

Indications

No indication recorded.